[{"date_created":"2020-05-17T22:00:44Z","month":"06","page":"282-289","intvolume":"        20","status":"public","publication":"Current opinion in allergy and clinical immunology","department":[{"_id":"Bio"}],"quality_controlled":"1","isi":1,"publisher":"Wolters Kluwer","type":"journal_article","author":[{"full_name":"Singer, Judit","first_name":"Judit","last_name":"Singer","orcid":"0000-0002-8777-3502","id":"36432834-F248-11E8-B48F-1D18A9856A87"},{"first_name":"Josef","full_name":"Singer, Josef","last_name":"Singer"},{"last_name":"Jensen-Jarolim","full_name":"Jensen-Jarolim, Erika","first_name":"Erika"}],"day":"01","title":"Precision medicine in clinical oncology: the journey from IgG antibody to IgE","citation":{"mla":"Singer, Judit, et al. “Precision Medicine in Clinical Oncology: The Journey from IgG Antibody to IgE.” <i>Current Opinion in Allergy and Clinical Immunology</i>, vol. 20, no. 3, Wolters Kluwer, 2020, pp. 282–89, doi:<a href=\"https://doi.org/10.1097/ACI.0000000000000637\">10.1097/ACI.0000000000000637</a>.","chicago":"Singer, Judit, Josef Singer, and Erika Jensen-Jarolim. “Precision Medicine in Clinical Oncology: The Journey from IgG Antibody to IgE.” <i>Current Opinion in Allergy and Clinical Immunology</i>. Wolters Kluwer, 2020. <a href=\"https://doi.org/10.1097/ACI.0000000000000637\">https://doi.org/10.1097/ACI.0000000000000637</a>.","ieee":"J. Singer, J. Singer, and E. Jensen-Jarolim, “Precision medicine in clinical oncology: the journey from IgG antibody to IgE,” <i>Current opinion in allergy and clinical immunology</i>, vol. 20, no. 3. Wolters Kluwer, pp. 282–289, 2020.","ista":"Singer J, Singer J, Jensen-Jarolim E. 2020. Precision medicine in clinical oncology: the journey from IgG antibody to IgE. Current opinion in allergy and clinical immunology. 20(3), 282–289.","ama":"Singer J, Singer J, Jensen-Jarolim E. Precision medicine in clinical oncology: the journey from IgG antibody to IgE. <i>Current opinion in allergy and clinical immunology</i>. 2020;20(3):282-289. doi:<a href=\"https://doi.org/10.1097/ACI.0000000000000637\">10.1097/ACI.0000000000000637</a>","apa":"Singer, J., Singer, J., &#38; Jensen-Jarolim, E. (2020). Precision medicine in clinical oncology: the journey from IgG antibody to IgE. <i>Current Opinion in Allergy and Clinical Immunology</i>. Wolters Kluwer. <a href=\"https://doi.org/10.1097/ACI.0000000000000637\">https://doi.org/10.1097/ACI.0000000000000637</a>","short":"J. Singer, J. Singer, E. Jensen-Jarolim, Current Opinion in Allergy and Clinical Immunology 20 (2020) 282–289."},"doi":"10.1097/ACI.0000000000000637","language":[{"iso":"eng"}],"_id":"7864","abstract":[{"lang":"eng","text":"Purpose of review: Cancer is one of the leading causes of death and the incidence rates are constantly rising. The heterogeneity of tumors poses a big challenge for the treatment of the disease and natural antibodies additionally affect disease progression. The introduction of engineered mAbs for anticancer immunotherapies has substantially improved progression-free and overall survival of cancer patients, but little efforts have been made to exploit other antibody isotypes than IgG.\r\nRecent findings: In order to improve these therapies, ‘next-generation antibodies’ were engineered to enhance a specific feature of classical antibodies and form a group of highly effective and precise therapy compounds. Advanced antibody approaches include among others antibody-drug conjugates, glyco-engineered and Fc-engineered antibodies, antibody fragments, radioimmunotherapy compounds, bispecific antibodies and alternative (non-IgG) immunoglobulin classes, especially IgE.\r\nSummary: The current review describes solutions for the needs of next-generation antibody therapies through different approaches. Careful selection of the best-suited engineering methodology is a key factor in developing personalized, more specific and more efficient mAbs against cancer to improve the outcomes of cancer patients. We highlight here the large evidence of IgE exploiting a highly cytotoxic effector arm as potential next-generation anticancer immunotherapy."}],"date_published":"2020-06-01T00:00:00Z","article_processing_charge":"No","issue":"3","volume":20,"publication_status":"published","year":"2020","oa_version":"None","article_type":"original","publication_identifier":{"eissn":["14736322"]},"external_id":{"isi":["000561358300010"]},"scopus_import":"1","date_updated":"2023-08-21T06:28:52Z","user_id":"4359f0d1-fa6c-11eb-b949-802e58b17ae8"}]